Brent N. Rexer

2.6k total citations
38 papers, 1.8k citations indexed

About

Brent N. Rexer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Brent N. Rexer has authored 38 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 20 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Brent N. Rexer's work include HER2/EGFR in Cancer Research (19 papers), Advanced Breast Cancer Therapies (10 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Brent N. Rexer is often cited by papers focused on HER2/EGFR in Cancer Research (19 papers), Advanced Breast Cancer Therapies (10 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Brent N. Rexer collaborates with scholars based in United States, Spain and Japan. Brent N. Rexer's co-authors include Carlos L. Arteaga, Todd W. Miller, Joan T. Garrett, Jeffrey A. Engelman, David E. Ong, Rebecca S. Cook, Wen Zheng, D E Ong, Anindita Chakrabarty and Rafael Mira-y-Lopez and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Brent N. Rexer

35 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brent N. Rexer United States	21	1.0k	910	407	334	332	38	1.8k
Edward Rosfjord United States	19	938 0.9×	1.0k 1.1×	383 0.9×	358 1.1×	271 0.8×	39	1.9k
Ariella B. Hanker United States	15	942 0.9×	759 0.8×	445 1.1×	211 0.6×	453 1.4×	41	1.6k
Neil A. O’Brien United States	23	821 0.8×	1.0k 1.1×	455 1.1×	375 1.1×	265 0.8×	55	1.6k
Karin Beelen Netherlands	12	942 0.9×	1.1k 1.2×	438 1.1×	410 1.2×	403 1.2×	21	1.7k
Yasir H. Ibrahim United States	12	1.1k 1.1×	828 0.9×	305 0.7×	163 0.5×	249 0.8×	22	1.6k
Joan T. Garrett United States	19	1.2k 1.2×	1.1k 1.3×	392 1.0×	599 1.8×	229 0.7×	30	2.0k
Lars Damstrup Denmark	19	902 0.9×	910 1.0×	452 1.1×	208 0.6×	226 0.7×	43	1.9k
Cordula Petersen Germany	26	1.0k 1.0×	870 1.0×	435 1.1×	212 0.6×	493 1.5×	60	2.0k
Laurent Hennequin France	22	1.5k 1.5×	973 1.1×	500 1.2×	149 0.4×	341 1.0×	52	2.7k
Jane Kendrew United Kingdom	22	1.5k 1.5×	1.1k 1.2×	638 1.6×	313 0.9×	561 1.7×	33	2.7k

Countries citing papers authored by Brent N. Rexer

Since Specialization

Citations

This map shows the geographic impact of Brent N. Rexer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brent N. Rexer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brent N. Rexer more than expected).

Fields of papers citing papers by Brent N. Rexer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brent N. Rexer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brent N. Rexer. The network helps show where Brent N. Rexer may publish in the future.

Co-authorship network of co-authors of Brent N. Rexer

This figure shows the co-authorship network connecting the top 25 collaborators of Brent N. Rexer. A scholar is included among the top collaborators of Brent N. Rexer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brent N. Rexer. Brent N. Rexer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

González-Ericsson, Paula I., Nisha Unni, Komal Jhaveri, et al.. (2025). Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer. Clinical Cancer Research. 31(17). 3652–3661.

Rexer, Brent N., Vandana G. Abramson, Sara Nunnery, et al.. (2024). Abstract PO3-02-03: Ketogenic diet and letrozole to inhibit PI3K signaling in ER+ breast cancer. Cancer Research. 84(9_Supplement). PO3–2.

Tolaney, Sara M., Muralidhar Beeram, J. Thaddeus Beck, et al.. (2022). Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. Frontiers in Oncology. 11. 810023–810023. 11 indexed citations

Sánchez, Violeta, et al.. (2022). Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer. Breast Cancer Research and Treatment. 197(2). 307–317. 2 indexed citations

Sherry, Alexander D., Ingrid A. Mayer, D.N. Ayala-Peacock, et al.. (2020). Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity. Clinical Breast Cancer. 20(4). 344–352.e1. 13 indexed citations

Rimawi, Mothaffar F., Polly Niravath, Tao Wang, et al.. (2019). TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research. 26(4). 821–827. 34 indexed citations

Hanker, Ariella B., Mónica V. Estrada, Giampaolo Bianchini, et al.. (2017). Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Research. 77(12). 3280–3292. 78 indexed citations

Schwarz, Luis J., Katherine E. Hutchinson, Brent N. Rexer, et al.. (2017). An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. JNCI Journal of the National Cancer Institute. 109(11). 35 indexed citations

Joly, Meghan M., Donna J. Hicks, Bayley A. Jones, et al.. (2016). Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2 -Amplified Breast Cancers. Cancer Research. 76(16). 4752–4764. 69 indexed citations

10.

Beeram, M., Sara M. Tolaney, J. Thaddeus Beck, et al.. (2016). A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology. 27. vi556–vi556. 8 indexed citations

11.

Bi, Xiaohong, et al.. (2014). Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy. Journal of Biomedical Optics. 19(2). 25001–25001. 45 indexed citations

12.

Young, Christian D., Adam D. Pfefferle, Philip Owens, et al.. (2013). Conditional Loss of ErbB3 Delays Mammary Gland Hyperplasia Induced by Mutant PIK3CA without Affecting Mammary Tumor Latency, Gene Expression, or Signaling. Cancer Research. 73(13). 4075–4085. 20 indexed citations

13.

Rexer, Brent N. & Carlos L. Arteaga. (2013). Optimal Targeting of HER2–PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications. Cancer Research. 73(13). 3817–3820. 42 indexed citations

14.

Rexer, Brent N. & Carlos L. Arteaga. (2012). Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications. Critical Reviews™ in Oncogenesis. 17(1). 1–16. 262 indexed citations

15.

Yang, Xuemei, Alexa B. Turke, Jie Qi, et al.. (2011). Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer. Cancer Research. 71(18). 5965–5975. 9 indexed citations

16.

Miller, Todd W., Brent N. Rexer, Joan T. Garrett, & Carlos L. Arteaga. (2011). Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Research. 13(6). 224–224. 359 indexed citations

17.

Rexer, Brent N., Amy‐Joan L. Ham, Cammie Rinehart, et al.. (2011). Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene. 30(40). 4163–4174. 112 indexed citations

18.

Rexer, Brent N., Jeffrey A. Engelman, & Carlos L. Arteaga. (2009). Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle. 8(1). 18–22. 68 indexed citations

19.

Rexer, Brent N. & David E. Ong. (2002). A Novel Short-Chain Alcohol Dehydrogenase from Rats with Retinol Dehydrogenase Activity, Cyclically Expressed in Uterine Epithelium1. Biology of Reproduction. 67(5). 1555–1564. 31 indexed citations

20.

Williams, John B., Brent N. Rexer, Sutha K. John, et al.. (1997). The Human HNP36 Gene Is Localized to Chromosome 11q13 and Produces Alternative Transcripts That Are Not Mutated in Multiple Endocrine Neoplasia, Type 1 (MEN I) Syndrome. Genomics. 42(2). 325–330. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact